Implementing Bispecific Treatments

EP: 1.Bispecific Antibodies in DLBCL: Therapeutic Potential

EP: 2.Efficacy Insights on Bispecific Antibodies in DLBCL

EP: 3.Bispecific Antibodies in DLBCL Trials

EP: 4.Bispecific Antibodies in DLBCL: Patient Response

EP: 5.Future Insights on Bispecific Therapies

EP: 6.Overcoming DLBCL Treatment Hurdles

EP: 7.Patient Education and Monitoring in DLBCL Treatment

Now Viewing

EP: 8.Implementing Bispecific Treatments

EP: 9.Bispecific Toxicity Management in DLBCL Care

EP: 10.Multidisciplinary Bispecific Care

EP: 11.Pharmacists: Bispecifics and Operational Role

EP: 12.Strategies for Reducing Bispecific Therapy Toxicities

EP: 13.Unmet Needs in Bispecific Therapy Access

EP: 14.Implementing Bispecific Antibodies in Lymphoma Care

This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.

In this segment, Mahmoudjafari and Mancini discuss the implementation of step-up dosing for bispecific therapies in lymphoma patients. Mancini details the multifaceted approach at his institution, including policy development, patient guidelines, referral processes, and outpatient monitoring. He emphasizes the importance of education and collaboration with health care providers overseeing chimeric antigen receptor (CAR) T-cell therapies.

Ali shares insights into the administration of bispecifics at his center, currently using inpatient ramp-up followed by outpatient maintenance. The discussion delves into considerations for decision-making when selecting bispecifics, highlighting institutional preferences, insurance coverage, and the availability of CAR T-cell therapy options. The conversation provides valuable perspectives on the challenges and preparations involved in implementing bispecific therapies, emphasizing the evolving landscape of lymphoma treatment.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.